Caribou Biosciences (CRBU) Other financing activities (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Other financing activities of $468000.0 for Q1 2026, little changed year-over-year from $468000.0 in Q1 2025, and up 68.95% quarter-over-quarter from $277000.0 in Q3 2025.
Caribou Biosciences (CRBU) Other financing activities (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Other financing activities for 6 consecutive years, with $468000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities changed 0.0% year-over-year to $468000.0; the TTM figure through Mar 2026 stood at $745000.0 (up 4.2% YoY), while the FY2025 annual figure was $745000.0, down 18.49% from the prior year.
- Other financing activities grew to $468000.0 in Q1 2026 per CRBU's latest filing, from $277000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $17.4 million in Q2 2023 and bottomed at -$17.4 million in Q3 2023.
- Historically, Other financing activities has averaged $1.9 million across 4 years, with a median of $372500.0 in 2025.
- On a YoY basis, Other financing activities climbed as much as 101.4% in 2024 and fell as far as 99.99% in 2024.
- Caribou Biosciences' Other financing activities stood at $17.3 million in 2023, then tumbled by 99.99% to $1000.0 in 2024, then jumped by 27600.0% to $277000.0 in 2025, then jumped by 68.95% to $468000.0 in 2026.
- Business Quant data shows CRBU's Other financing activities at $468000.0 in Q1 2026, $277000.0 in Q3 2025, and $468000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,000.00 |
| Mar 31, 2026 | 468,000.00 |
| Sep 30, 2025 | 277,000.00 |
| Sep 30, 2025 | 277,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 244,000.00 |
| Sep 30, 2024 | 244,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 667,000.00 |
| Mar 31, 2024 | 667,000.00 |
| Dec 31, 2023 | 17.29 Mn |
| Dec 31, 2023 | 17.29 Mn |
| Sep 30, 2023 | -17.45 Mn |
| Sep 30, 2023 | -17.45 Mn |
| Jun 30, 2023 | 17.45 Mn |
| Jun 30, 2023 | 17.45 Mn |